Introduction
Pregabalin (PGB) is a newer antiepileptic drug (AED) licensed in Germany and several other European countries as add-on treatment for partial epilepsies as well as for generalised anxiety disorder and neuropathic pain in adults. The putative mechanism of action of PGB is to reduce the synaptic release of several neurotransmitters by binding to the a2-d-protein. 1 Efficacy and safety have been proven in several controlled studies. [2] [3] [4] [5] These trials, however, only partially reflect clinical practice since they are conducted in highly selected patient groups over only relatively short treatment periods and have to obey fixed treatment schedules. 6 Furthermore, adverse events that become overt only after longer treatment periods or that occur only rarely may go undetected in short-term studies. One way of generating more information is to assess the retention rate as a combined measure of efficacy and tolerability in long-term studies. [7] [8] [9] This evaluation was part of the quality-assurance process in our centre.
Methods
Bethel Epilepsy Centre is a tertiary referral centre for epilepsy. All patients who had been started on PGB add-on therapy for epilepsy between September 2004 and November 2005 have been followed-up after 3, 6 and 12 months, mainly (80.9%) by telephone-call. Treatment was started either on an in-patient or an out-patient basis or while the patients were under the care of the Berufsbildungswerk, a vocational training centre for young adults with epilepsy. Data were collected prospectively as part of clinical routine. As this was not a formal study, there were no regulations concerning dose titration or target doses. Patients were also included for evaluation if they were treated with PGB beyond the limits of licensing (''off-label use''). All patients were advised to keep seizure diaries.
We assessed demographical data, data concerning epilepsy type and time-course, seizure frequency for each seizure type (for the last week, last 4 weeks and last 3 months), occurrence of status epilepticus (convulsive or non-convulsive), day of last seizure, body-weight, dose titration and antiepileptic comedication. Furthermore, patients were asked if they had had any adverse events and-if PGB had been withdrawn-they were asked to state the reasons for withdrawal. Special events (e.g. concomitant illness) were documented. During follow-up, seizure frequency, date of last seizure, body-weight and co-AEDs were documented in the same form as in the initial documentation.
Statistical analysis was done with descriptive and explorative methods. Response to PGB was evaluated by comparing seizure frequency over all seizure types between a period of 4 weeks before starting PGB and a period of 4 weeks before last follow-up. In cases where only data about the last week were available (5 out of 42 patients at t 0 and 3 out of 42 at t 12 ) the 4-week frequency was estimated from the available data (see Table 2 ).
Retention rate was the primary parameter, but efficacy of PGB was assessed additionally and classified as follows-seizure-free: no seizures within the last 4 weeks (the exact periods of seizurefreedom were documented); responder: seizure reduction 50% or more compared to baseline but not seizure-free; non-responder: change of seizure frequency less than 50%; worsening of seizure frequency: increase of more than 50% compared to baseline.
A Kaplan-Meier curve was used to illustrate the time-course of the retention rate.
Some patients could not be contacted exactly at the planned time-points. If the last follow-up was done after 365 days, time of evaluation was set back to 365 days.
Adverse events (AEs) were evaluated by open question. Besides the spontaneous answers patients were explicitly asked for their body weight.
Results
In total, 111 patients were started on PGB, but four patients were lost to follow-up, and two died during the follow-up period (censored data); 105 patients have been followed-up about 12 months or until PGB therapy was stopped (median follow-up time = 221 days).
No post-mortem has been done in the two patients who died, but there was no apparent association with the PGB treatment. One patient has been found dead in his apartment. This 32 years old male patient had had episodes of status epilepticus before. Because of this, it was assumed that he had died during status. The other, a 49-year-old male patient, had also a diagnosis of schizophrenia and had refused sufficient fluid intake for several days during a heat period and collapsed while being with a care-giver. It was assumed that he had had a cardiac arrest.
Mean age of the 105 patients was 38.1 AE 13.1 years (range 16.3-80.9 years). The epilepsy syndromes were classified as focal in 80 patients (76.2%), multifocal in 20 (19.0%), as epilepsy with both focal and generalised seizures in 4 (3.8%) and not classified in 1 (1%).
9 patients had a learning disability and 28 an intellectual disability (13 mild, 11 moderate, 4 severe), and 40 patients had another psychiatric diagnosis (23 personality disorder, 6 history of or current psychosis, 7 anxiety disorder, 5 depression, 1 dysthymia; number exceeds 40 as some persons had more than one diagnosis).
Sufficient data about the drug history could be obtained in 87 patients. These patients had been treated with 8.2 AE 2.6 AEDs as mean in mono-or combination therapy before initiating PGB. For the comedication on initiation of PGB see Table 1 . Two patients were started on PGB as second AED because of concomitant anxiety disorder. 13 patients (12.4%) had already a vagus nerve stimulator.
Titration of PGB
As this was not a formal study, no fixed titration schemes were set. Titration rates were adapted to the individual situation, especially if AEs occurred. After 6 months, most patients were treated with PGB doses within the recommended dose range between 150 and 600 mg: 25.4% were on 300 mg/day and 28.8% on 600 mg/day (mean 430 AE 210 mg/day, range 75-900 mg/day), and after 12 months, 19.0% out of 42 patients were on 300 mg/day and 33.3% on 600 mg/day (523 AE 185 mg/day, 200-900 mg/day).
Retention rate and response
42 (40%) out of 105 patients were still treated with PGB after 12 months. Reasons for withdrawal in the 63 patients who terminated PGB therapy were insufficient efficacy in 30 patients (47.6%), adverse events in 8 (12.7%) and a combination of both in 21 (33.3%). See Fig. 1 for the retention rate.
After 12 months, 6 patients (5.7%) were seizure-free for at least 1 month (4.8% for at least 3 months, 2.4% for at least 6 months; see Table 2 for seizure-frequencies at baseline). One of them, however, had had surgical treatment for his epilepsy while being on PGB. b In relation to patients on initiation of PGB and after 12 months on PGB. Information about the exact date of the last seizure was available in 5 out of these 6 patients. Exact time of seizure freedom was 43, 149, 156, 305 and 314 days. Out of the responders (n = 18; 17.1%), a VNS had been implanted in one, and one had had surgical treatment. None of the nonresponders had either brain operation or VNS implantation. 8 patients (7.6%) were non-responders, and another 6 (5.7%) had a worsening of their seizure frequency of more than 50% compared to baseline and in 63 patients (60.0%) PGB was withdrawn (insufficient information about four patients).
See Table 2 for changes of seizure frequencies from baseline to 12-month follow-up.
In the patient group still treated with PGB after 12 months (n = 42), the number of concomitant drugs had been reduced from 2.0 AE 0.75 to 1.6 AE 0.63 (p < 0.01; two-sided, exact Wilcoxon-test). All 42 patients were treated with concomitant AEDs. There were no more patients with 5 AEDs (t 0 3.8%, n = 4). See Table 1 for details.
Adverse events
See Table 3 for AEs. Most AEs were only transient, especially during up-titration of PGB.
See Fig. 2 for changes of body weight under PGB.
Discussion
The efficacy and safety of PGB as an AED have been proven in several controlled studies. [2] [3] [4] [5] Recently, a Cochrane review summarized that PGB when used as an add-on drug for treatment-resistant partial epilepsy was significantly more effective than placebo at achieving a 50% or greater seizure reduction. 10 These studies, however, as premarketing studies in general, provide only limited data about the usefulness of an AED in clinical practice as they apply a rigid set of inclusion and exclusion criteria, observe fixed titration schemes and refer to a limited treatment period. Open-label extensions of randomised placebo-controlled trials (RCTs) do provide information about longer observation periods, represent, however, a selected population insofar as they include only patients who completed the preceding RCT.
Open studies like the one reported here offer information about a broad population often not covered adequately by other types of studies and give the opportunity to titrate the doses of the studydrug and comedication individually. Patients included in our study had highly refractory forms of epilepsy and also in many cases learning or intellectual disability (37 patients) or psychiatric comorbidity (40 patients). Obviously, the study has weaknesses: it is more difficult to get precise information about seizure frequency, even more if the patient suffers from different seizure types, and about side-effects by telephone interview. As there was no fixed protocol, not only the study-drug but also concomitant drugs may have been changed or patients may have had epilepsy surgery. The most robust parameter evaluated by our study is the retention rate which is an accepted marker of combined efficacy and tolerability of AEDs. [7] [8] [9] The retention rate of 40% for PGB after 12 months that we found is slightly higher than that reported by Bauer who found 33 out of 103 patients still treated with PGB after 52 weeks 11 and comparable to the one reported by Huber in patients with epilepsy and intellectual disability living in long-term residential care (n = 33, retention rate after 12 months 40.6%). 12 It is considerably lower than the retention rate of 59.4% after 1-year found by reviewing four long-term open-label studies. 13 Prior to participating in these studies, however, 968 out of 1.480 patients had completed an RCT evaluating PGB so that these studies reflect, as mentioned above, a selected population. The retention rate of 40% is also considerably lower than the rate of 60.4% found by Carreno et al. 14 It is, however, difficult to compare that study due to its retrospective character. It is possible that their patients had less refractory epilepsies than ours as they had to have one to three failed drugs before the introduction of PGB while ours had 8.2 AE 2.6 failed AEDs before. The same applies for the audit study by Valentin et al. 15 who found a retention rate of 65% after 12 months in patients who had had a median number of 3 AEDs before commencing PGB. 15 Further data concerning efficacy and tolerability were collected. After 12 months, 6 patients (5.7%) were seizure-free for at least 4 weeks before the last follow-up, 4.8% for at least 3 months, 2.4% for at least 6 months. As this was a purely observational study with no restrictions according to comedication or other therapeutic procedures, one of them had had surgical treatment for his epilepsy, so the therapeutic success cannot simply be attributed to the PGB treatment. The same limitation applies for those who experienced an increase in seizure frequency, i.e. changes in comedication or other factors potentially influencing seizurefrequency may be (partially) responsible. This may, however, also be true for other open-label studies. The seizure-free rate in our study is smaller than that reported by Ryvlin (8.9% over the last 6 months and 5.8% over the last year of treatment) but the limitations mentioned above do apply here again. 13 It is surprising that 40% of the patients remained on PGB therapy, but only 22.8% of patients experienced a clinically relevant improvement of seizure frequency under PGB therapy (sum of seizure-free patients and responders). Several hypotheses have to be discussed: one is that they had an improvement not of seizure frequency but of seizure severity which was not assessed by the telephone interview. Another hypothesis is that these patients experienced a positive psychotropic effect of PGB which would be plausible as also anxiolytic properties have been ascribed to the drug or that they had less side-effects than under previous drugs. It may, however, be possible that doctors tended to prescribe PGB further even in patients with no detectable gain from the drug as these patients represent a population with highly treatment-resistant epilepsies who had no other therapeutic options or that doctors were reluctant to change a therapeutic regimen initiated by a referral centre for epilepsy.
PGB was generally well tolerated, weight gain being the most frequently mentioned AE. As AEs were not assessed by systematic questioning or examination but by spontaneous report to open questioning, no further specification of some AE categories is possible, and the frequency of AEs may generally be underestimated.
Conclusions
Despite the above mentioned limitations it can be concluded from our observational study in a naturalistic setting that PGB is a new therapeutic option as add-on therapy for patients with highly refractory focal epilepsies although the therapeutic success that can be expected in this group of patients is generally limited. Among the adverse events, weight gain seems to be the most frequent, although not necessarily leading to withdrawal of PGB.
